Quoin Pharmaceuticals, Ltd. (QNRX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Quoin Pharmaceuticals, Ltd. (QNRX) closed at USD 4.10 on 2026-10-14, a change of -68.4 % over the past year, with a market capitalization of USD 19.36M.

Quoin Pharmaceuticals, Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Quoin Pharmaceuticals, Ltd. key figures

Previous close

USD 4.10 (2026-10-14)

1-year change

-68.4 %

Market cap

USD 19.36M

Enterprise value

USD -682,424

P/E ratio (trailing)

-0.73

P/E ratio (forward)

-1.27

EPS (trailing)

-5.51

EPS (forward)

-3.19

PEG ratio

n/a

Price to book

2.06

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.54

Employees

4

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Quoin Pharmaceuticals, Ltd. and compare it with other stocks.